Merck Wins First Femur-Related Fosamax Suit

Law360, New York (April 29, 2013, 8:28 PM EDT) -- Merck & Co. on Monday triumphed in a New Jersey bellwether trial over femur fractures allegedly caused by its bone drug Fosamax, after a jury ruled that the nature of the plaintiff’s injury ruled out Fosamax as a potential cause.

A New Jersey federal jury found for the drugmaker, deciding plaintiff Bernadette Glynn’s femur fracture could not have been caused by Fosamax, a drug prescribed to treat diminished bone density, agreeing that Glynn’s fracture was consistent with a traumatic injury rather than compromised bone health. The...
To view the full article, register now.

Related

Sections

Case Information

Case Title

GLYNN et al v. MERCK SHARP & DOHME CORP.


Case Number

3:11-cv-05304

Court

New Jersey

Nature of Suit

Personal Inj. Prod. Liability

Judge

Joel A. Pisano

Date Filed

September 15, 2011

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.